Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.9%

235 terminated/withdrawn out of 1581 trials

Success Rate

82.3%

-4.3% vs industry average

Late-Stage Pipeline

30%

482 trials in Phase 3/4

Results Transparency

63%

691 of 1090 completed trials have results

Key Signals

81 recruiting691 with results191 terminated44 withdrawn

Enrollment Performance

Analytics

Phase 2

478(33.7%)

Phase 1

400(28.2%)

Phase 3

360(25.4%)

Phase 4

122(8.6%)

N/A

45(3.2%)

Early Phase 1

12(0.8%)

1417Total

Phase 2(478)

Phase 1(400)

Phase 3(360)

Phase 4(122)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1581)

Showing 20 of 1581 trials

NCT07545226Phase 1Completed

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.

Role: lead

NCT05565560Phase 3Completed

A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

Role: lead

NCT07851220Phase 3Recruiting

A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy

Role: lead

NCT06072482Phase 4Recruiting

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Role: lead

NCT07226765Phase 3Active Not Recruiting

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Role: lead

NCT07614776Phase 3Recruiting

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Role: lead

NCT07013578Not ApplicableRecruiting

TIDHI Mental Health in IBD Patients Study

Role: collaborator

NCT07441252Phase 2Active Not Recruiting

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Role: lead

NCT07297979Phase 1Recruiting

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Role: lead

NCT05920356Phase 3Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Role: lead

NCT07037758Phase 1Recruiting

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Role: lead

NCT05789303Phase 2Recruiting

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Role: collaborator

NCT07832799Phase 1Not Yet Recruiting

Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

Role: lead

NCT07213674Phase 3Recruiting

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Role: lead

NCT06700343Phase 3Active Not Recruiting

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Role: lead

NCT07229157Phase 1Completed

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Role: lead

NCT07037433Phase 3Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Role: lead

NCT06814496Phase 1Recruiting

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Role: collaborator

NCT03836040Phase 3Active Not Recruiting

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

Role: lead

NCT07203053Phase 2Recruiting

A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

Role: collaborator